Liraglutide injection represents Meitheal’s first commercial injector pen product and its first commercial diabetes medication. In 2023, Meitheal secured an exclusive commercial license for ...

A liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is available as an injector pen and used along with diet and exercise to improve glycemic control in adults and ...

NovoPen ®, the first insulin pen injector, was introduced in 1985. This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes ...